Table 1.
Patient Characteristics and Forodesine and dGuo-lnduced Apoptosis
| % Viabilitya | ||||||
|---|---|---|---|---|---|---|
| Patient No. | Age (years) | Sex | Diagnosis | WBC 103/µL | Untreated | Treated |
| 1 | 11 | M | Pre–B-ALL | 10 | 84 | 70 |
| 2 | 11 | F | Pre–B-ALL | 2.4 | 87 | 77 |
| 3 | 2 | M | AML | 28.9 | 78 | 69 |
| 4 | 19 | M | Pre–B-ALL | 2.5 | 64 | 61 |
| 5 | 15 | M | Pre–B-ALL | 0.6 | 97 | 95 |
| 6 | 21 | M | Pre–B-ALL | 75.9 | 81 | 41 |
| 7 | 5 | M | Pre–B-ALL | 11.1 | 82 | 74 |
| 8 | 25 | M | T-ALL | 14.1 | – | – |
| 9 | 7 mo | M | Pre–B-ALL | 34.7 | – | – |
| 10 | 19 | M | Pre–B-ALL | 26 | – | – |
| 11 | 1 | M | Pre–B-ALL | 207 | 70 | 50 |
| 12 | 15 | M | Pre–B-ALL | 116 | – | – |
Two adult patients with B-ALL for clinical and pharmacology study on forodesine at a dose of 80 mg/m2/day (30 min infusion daily x 5).
Patient 1 = No. 9001.
Patient 2 = No. 9002.
Abbreviations: B-ALL = B-cell acute lymphoblastic leukemia; WBC = white blood cell.
a
Leukemia blasts were incubated in vitro without (untreated) or with 2 µM forodesine and 20 µM dGuo and % viability was measured by annexin/propidium iodide binding assay.